Ted Williams
Chief Tech/Sci/R&D Officer at Tissue Repair Co.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christopher Reinhard | M | 70 |
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 25 years |
Jeffrey J. Miller | M | - |
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Tyle M. Dylan-Hyde | M | 62 |
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 13 years |
Dennis Mulroy | M | 69 |
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA. | 7 years |
Steven Mento | M | 72 |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | 5 years |
Randall Moreadith | M | 70 |
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA. | 1 years |
Mark Gergen | M | 61 |
Advanced Tissue Sciences, Inc.
| 4 years |
Harry E. Gruber | M | 72 |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | 7 years |
Alana McNulty | F | 61 |
Advanced Tissue Sciences, Inc.
| 7 years |
Paul A. Foster | M | 70 |
Post-Hypothermia Corp.
Post-Hypothermia Corp. Medical SpecialtiesHealth Technology Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA. | - |
Anthony Andrasfay | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 4 years |
Patricia L. Novak | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 6 years |
Cleland C. Landolt | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 6 years |
Juliet Singh | M | 64 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 2 years |
Nikhil Atul Mehta | M | 67 |
Advanced Tissue Sciences, Inc.
| 2 years |
Mark McCutchen | M | - |
Tissue Repair Co.
Tissue Repair Co. Medical SpecialtiesHealth Technology Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA | - |
Michael V. Swanson | M | 69 |
Advanced Tissue Sciences, Inc.
| 10 years |
Ronald Simon | M | 85 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 4 years |
Joseph R. Kletzel | M | 74 |
Advanced Tissue Sciences, Inc.
| 4 years |
Stephen Aselage | M | 73 |
Advanced Tissue Sciences, Inc.
| 3 years |
Dale A. Stringfellow | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 5 years |
Julie A. DeMeules | F | 71 |
Advanced Tissue Sciences, Inc.
| 9 years |
Francis Burrows | M | - |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 23 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ted Williams
- Personal Network